{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T09:14:27Z","timestamp":1794647667481,"version":"4.9.1"},"reference-count":173,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.eururo.2013.03.004","type":"journal-article","created":{"date-parts":[[2013,3,13]],"date-time":"2013-03-13T02:15:16Z","timestamp":1363140916000},"page":"118-140","source":"Crossref","is-referenced-by-count":989,"title":["EAU Guidelines on the Treatment and Follow-up of Non-neurogenic Male Lower Urinary Tract Symptoms Including Benign Prostatic Obstruction"],"prefix":"10.1016","volume":"64","author":[{"given":"Matthias","family":"Oelke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Bachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Descazeaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Emberton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavros","family":"Gravas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin C.","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"N'Dow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rgen","family":"Nordling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean J.","family":"de la Rosette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2013.03.004_bib0005","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.eursup.2009.02.001","article-title":"Medical treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia","volume":"8","author":"Michel","year":"2009","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.eururo.2013.03.004_bib0010","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.eururo.2004.07.016","article-title":"EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines)","volume":"46","author":"Madersbacher","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0015","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.eururo.2009.04.028","article-title":"EAU guidelines on neurogenic lower urinary tract dysfunction","volume":"56","author":"St\u00f6hrer","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0870","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.eururo.2012.08.047","article-title":"EAU guidelines on assessment and nonsurgical management of urinary incontinence","volume":"62","author":"Lucas","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0025","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1159\/000049840","article-title":"EAU guidelines for the management of urinary and male genital tract infections. Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU)","volume":"40","author":"Naber","year":"2001","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0030","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1016\/j.juro.2007.09.107","article-title":"2007 guideline for the management of ureteral calculi","volume":"178","author":"Preminger","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0035","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.eururo.2011.03.017","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update","volume":"59","author":"Babjuk","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0040","unstructured":"Oxford Centre for Evidence-based Medicine levels of evidence (March 2009). Centre for Evidence-based Medicine Web site. http:\/\/www.cebm.net\/index.aspx?o=1025. Accessed November 2011."},{"key":"10.1016\/j.eururo.2013.03.004_bib0045","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0022-5347(01)63011-8","article-title":"5-Year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study","volume":"160","author":"Flanigan","year":"1998","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0050","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0090-4295(98)00475-0","article-title":"Evaluation of patients with bladder outlet obstruction and mild international prostate symptom score followed up by watchful waiting","volume":"53","author":"Netto","year":"1999","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2013.03.004_bib0055","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/bmj.39010.551319.AE","article-title":"Self management for men with lower urinary tract symptoms: a randomised controlled trial","volume":"334","author":"Brown","year":"2007","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2013.03.004_bib0060","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/j.1464-410X.2009.08497.x","article-title":"The impact of self-management of lower urinary tract symptoms on frequency-volume chart measures","volume":"104","author":"Yap","year":"2009","journal-title":"BJU Int"},{"issue":"Suppl 2","key":"10.1016\/j.eururo.2013.03.004_bib0065","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1038\/sj.bjp.0706619","article-title":"A1-, a2- and b-adrenoreceptors in the urinary bladder, urethra and prostate","volume":"147","author":"Michel","year":"2006","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0070","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.urology.2004.07.031","article-title":"State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia","volume":"64","author":"Djavan","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2013.03.004_bib0075","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/sj.pcan.4500267","article-title":"Comparison of tamsulosin efficacy in subgroups of patients with lower urinary tract symptoms","volume":"1","author":"Michel","year":"1998","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2013.03.004_bib0080","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/sj.pcan.4500849","article-title":"Three months\u2019 treatment with the a1-blocker alfuzosin does not affect total or transition zone volume of the prostate","volume":"9","author":"Roehrborn","year":"2006","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2013.03.004_bib0085","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.juro.2007.09.084","article-title":"The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study","volume":"179","author":"Roehrborn","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0090","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.eururo.2009.09.035","article-title":"The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT Study","volume":"57","author":"Roehrborn","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0095","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0090-4295(01)01344-9","article-title":"Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia","volume":"58","author":"Boyle","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2013.03.004_bib0100","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa030656","article-title":"The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia","volume":"349","author":"McConnell","year":"2003","journal-title":"N Engl J Med"},{"issue":"Suppl 4","key":"10.1016\/j.eururo.2013.03.004_bib0105","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1464-410X.2005.05487.x","article-title":"Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system","volume":"95","author":"Barendrecht","year":"2005","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2013.03.004_bib0110","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.jcrs.2005.02.027","article-title":"Intraoperative floppy iris syndrome associated with tamsulosin","volume":"31","author":"Chang","year":"2005","journal-title":"J Cataract Refract Surg"},{"key":"10.1016\/j.eururo.2013.03.004_bib0115","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2165\/00003495-200666030-00002","article-title":"Effects of a1-adrenoceptor antagonists on male sexual function","volume":"66","author":"van Dijk","year":"2006","journal-title":"Drugs"},{"key":"10.1016\/j.eururo.2013.03.004_bib0120","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/pcan.2010.46","article-title":"Symptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPH","volume":"14","author":"Roehrborn","year":"2011","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2013.03.004_bib0125","first-page":"814","article-title":"Evidence for atrophy and apoptosis in the prostates of men given finasteride","volume":"81","author":"Rittmaster","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eururo.2013.03.004_bib0130","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.clinthera.2007.01.018","article-title":"A review of the clinical efficacy and safety of 5a-reductase inhibitors for the enlarged prostate","volume":"29","author":"Naslund","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.eururo.2013.03.004_bib0135","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1464-410X.2011.10195.x","article-title":"Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS)","volume":"108","author":"Nickel","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2013.03.004_bib0140","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S0090-4295(96)00353-6","article-title":"Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials","volume":"48","author":"Boyle","year":"1996","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2013.03.004_bib0145","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0090-4295(02)02114-3","article-title":"Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial","volume":"61","author":"Kirby","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2013.03.004_bib0150","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000019706","article-title":"Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia","volume":"34","author":"Debruyne","year":"1998","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0155","first-page":"CD006015","article-title":"Finasteride for benign prostatic hyperplasia","author":"Tacklind","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eururo.2013.03.004_bib0160","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0090-4295(02)01905-2","article-title":"Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia","volume":"60","author":"Roehrborn","year":"2002","journal-title":"Urology"},{"issue":"Suppl 3","key":"10.1016\/j.eururo.2013.03.004_bib0165","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1464-410X.2008.07497.x","article-title":"BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE","volume":"101","author":"Roehrborn","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2013.03.004_bib0170","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1056\/NEJM199802263380901","article-title":"The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia","volume":"338","author":"McConnell","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2013.03.004_bib0175","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0090-4295(97)00185-4","article-title":"Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia","volume":"49","author":"Andersen","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2013.03.004_bib0180","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0090-4295(02)01905-2","article-title":"ARIA3001 ARIA3002 and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia","volume":"60","author":"Roehrborn","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2013.03.004_bib0185","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/j.1464-410X.2005.05686.x","article-title":"Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies","volume":"96","author":"Roehrborn","year":"2005","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2013.03.004_bib0190","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa030660","article-title":"The influence of finasteride on the development of prostate cancer","volume":"349","author":"Thompson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2013.03.004_bib0195","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1056\/NEJMoa0908127","article-title":"Effect of dutasteride on the risk of prostate cancer","volume":"362","author":"Andriole","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2013.03.004_bib0200","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.urology.2006.03.006","article-title":"Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia","volume":"68","author":"Kaplan","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2013.03.004_bib0205","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/j.1464-410X.2006.06068.x","article-title":"Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence","volume":"97","author":"Roehrborn","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2013.03.004_bib0210","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3109\/13685530903440408","article-title":"Solifenacin treatment in men with overactive bladder: effects on symptoms and patient-reported outcomes","volume":"13","author":"Kaplan","year":"2010","journal-title":"Aging Male"},{"key":"10.1016\/j.eururo.2013.03.004_bib0215","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.urology.2009.09.007","article-title":"Efficacy and tolerability of fesoterodine in men with overactive bladder: a pooled analysis of 2 phase III studies","volume":"75","author":"Herschorn","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2013.03.004_bib0220","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1097\/01.ju.0000181823.33224.a0","article-title":"Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia","volume":"174","author":"Kaplan","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0225","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00345-007-0212-5","article-title":"Safety and efficacy of tolterodine extended release in men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia","volume":"25","author":"H\u00f6fner","year":"2007","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0230","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1001\/jama.296.19.2319","article-title":"Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder","volume":"296","author":"Kaplan","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2013.03.004_bib0235","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.urology.2008.06.067","article-title":"Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB","volume":"72","author":"Roehrborn","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2013.03.004_bib0240","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/00365590902836740","article-title":"Okayama Urological Research Group. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study","volume":"43","author":"Yokoyama","year":"2009","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0245","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S0022-5347(05)00483-0","article-title":"Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction","volume":"175","author":"Abrams","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0250","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.eururo.2005.12.050","article-title":"Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate","volume":"49","author":"\u00dcckert","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0255","first-page":"43","article-title":"Nitric oxide synthase and the lower urinary tract: possible implications for physiology and pathophysiology","volume":"175","author":"Andersson","year":"1995","journal-title":"Scand J Urol Nephrol Suppl"},{"key":"10.1016\/j.eururo.2013.03.004_bib0260","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.eururo.2012.02.033","article-title":"A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with \u03b1-blockers for lower urinary tract symptoms owing to benign prostatic hyperplasia","volume":"61","author":"Gacci","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0265","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.eururo.2009.04.033","article-title":"Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia [published correction appears in Eur Urol 2011;59:1082]","volume":"56","author":"Porst","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0270","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.eururo.2012.01.013","article-title":"Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial","volume":"61","author":"Oelke","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0275","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/sj.pcan.4500746","article-title":"Not all brands are created equal: a comparison of selected compounds of different brands of Serenoa repens extract","volume":"7","author":"Habib","year":"2004","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2013.03.004_bib0280","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1159\/000161128","article-title":"Comparison of the potency of different brands of Sereonoa repens extract on 5alpha-reductase types I and II in prostatic co-cultured epithelial and fibroblast cells","volume":"82","author":"Scaglione","year":"2008","journal-title":"Pharmacology"},{"key":"10.1016\/j.eururo.2013.03.004_bib0285","first-page":"CD001044","article-title":"Pygeum africanum for benign prostatic hyperplasia","author":"Wilt","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eururo.2013.03.004_bib0290","first-page":"CD001042","article-title":"Cernilton for benign prostatic hyperplasia","author":"Wilt","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eururo.2013.03.004_bib0295","first-page":"CD001423","article-title":"Serenoa repens for benign prostatic hyperplasia","author":"Tacklind","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eururo.2013.03.004_bib0300","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00228-004-0781-9","article-title":"Pharmacokinetics and pharmacodynamics of desmopressin administered orally versus intravenously at daytime versus night-time in healthy men aged 55\u201370 years","volume":"60","author":"Rembratt","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0305","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1046\/j.1464-410X.2002.02791.x","article-title":"Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men","volume":"89","author":"Mattiasson","year":"2002","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2013.03.004_bib0310","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.eururo.2007.01.027","article-title":"Desmopressin in the treatment of nocturia: a double-blind, placebo-controlled study","volume":"52","author":"van Kerrebroeck","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0315","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1097\/01.ju.0000136203.76320.f6","article-title":"Clinical experiences with desmopressin for long-term treatment of nocturia","volume":"172","author":"Lose","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0320","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.eururo.2012.07.004","article-title":"A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management\u2014a systematic review and meta-analysis","volume":"62","author":"Cornu","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0325","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/nau.20168","article-title":"Desmopressin treatment in nocturia; an analysis of risk factors for hyponatremia","volume":"25","author":"Rembratt","year":"2006","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2013.03.004_bib0330","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/nau.20038","article-title":"The risk of hyponatremia in older adults using desmopressin for nocturia: a systematic review and meta-analysis","volume":"23","author":"Weatherall","year":"2004","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2013.03.004_bib0335","doi-asserted-by":"crossref","first-page":"F1116","DOI":"10.1152\/ajprenal.00741.2010","article-title":"Gender difference in antidiuretic response to desmopressin","volume":"300","author":"Juul","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0340","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0302-2838(03)00367-1","article-title":"Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5\u03b1-reductase inhibitor dutasteride","volume":"44","author":"Barkin","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0345","doi-asserted-by":"crossref","first-page":"16","DOI":"10.5489\/cuaj.520","article-title":"Finasteride monotherapy maintains stable lower urinary tract symptoms in men with benign prostatic hyperplasia following cessation of alpha blockers","volume":"2","author":"Nickel","year":"2008","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.eururo.2013.03.004_bib0350","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.4065\/83.9.1002","article-title":"Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study","volume":"83","author":"MacDiarmid","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.eururo.2013.03.004_bib0355","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/00365590902836740","article-title":"Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study","volume":"43","author":"Yokoyama","year":"2009","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0360","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1097\/01.ju.0000173630.94559.fd","volume":"174","author":"Lee","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0365","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1016\/j.juro.2009.08.023","article-title":"Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency","volume":"182","author":"Kaplan","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0370","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.eururo.2008.11.026","article-title":"Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with a-blockers","volume":"56","author":"Chapple","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0375","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1001\/jama.296.19.2319","article-title":"Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial","volume":"296","author":"Kaplan","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2013.03.004_bib0380","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1742-1241.2010.02611.x","article-title":"Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review","volume":"65","author":"Kaplan","year":"2011","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.eururo.2013.03.004_bib0385","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.eururo.2011.03.054","article-title":"The role of antimuscarinics in the management of men with symptoms of overactive bladder associated with concomitant bladder outlet obstruction: an update","volume":"60","author":"Athanasopoulos","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0390","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.eururo.2012.07.003","article-title":"Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial","volume":"63","author":"Kaplan","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0395","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1046\/j.1464-410x.1999.00908.x","article-title":"Is transurethral resection of the prostate still justified?","volume":"83","author":"Madersbacher","year":"1999","journal-title":"Br J Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0400","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.eururo.2010.06.005","article-title":"Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement","volume":"58","author":"Ahyai","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0405","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1097\/01.ju.0000176740.76061.24","article-title":"The natural history of lower urinary tract dysfunction in men: minimum 10-year urodynamic followup of transurethral resection of prostate for bladder outlet obstruction","volume":"174","author":"Thomas","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0410","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00345-009-0496-8","article-title":"The clinical effectiveness of transurethral incision of the prostate: a systematic review of randomised controlled trials","volume":"28","author":"Lourenco","year":"2010","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0415","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.eururo.2008.03.033","article-title":"Antibiotic prophylaxis in urologic procedures: a systematic review","volume":"54","author":"Bootsma","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0420","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.juro.2008.03.058","article-title":"Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients","volume":"180","author":"Reich","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0425","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/13645700601159410","article-title":"Bipolar transurethral resection of the prostate\u2014technical modifications and early clinical experience","volume":"16","author":"Rassweiler","year":"2007","journal-title":"Minim Invasive Ther Allied Technol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0430","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.eururo.2009.06.037","article-title":"Bipolar versus monopolar transurethral resection of the prostate: a systematic review and meta-analysis of randomized controlled trials","volume":"56","author":"Mamoulakis","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0435","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.urology.2009.08.015","article-title":"Systematic review and meta-analysis of transurethral resection of the prostate versus minimally invasive procedures for the treatment of benign prostatic obstruction","volume":"75","author":"Burke","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2013.03.004_bib0440","first-page":"CD009629","article-title":"Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction","author":"Mamoulakis","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eururo.2013.03.004_bib0445","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1464-410X.2011.10222.x","article-title":"Results from an international multicentre double-blind randomized controlled trial on the perioperative efficacy and safety of bipolar vs monopolar transurethral resection of the prostate","volume":"109","author":"Mamoulakis","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2013.03.004_bib0875","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.eururo.2012.10.003","article-title":"Midterm results from an international multicentre randomised controlled trial comparing bipolar with monopolar transurethral resection of the prostate","volume":"63","author":"Mamoulakis","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0455","unstructured":"Mamoulakis C, Schulze M, Skolarikos A, et al. Bipolar versus monopolar transurethral resection of the prostate: evaluation of the impact on overall sexual function in an international randomized controlled trial setting. BJU Int. In press."},{"key":"10.1016\/j.eururo.2013.03.004_bib0460","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.eururo.2009.01.028","article-title":"Four-year outcome of a prospective randomised trial comparing bipolar plasmakinetic and monopolar transurethral resection of the prostate","volume":"55","author":"Autorino","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0465","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1111\/j.1464-410X.2010.09401.x","article-title":"Bipolar transurethral resection in saline vs traditional monopolar resection of the prostate: results of a randomized trial with a 2-year follow-up","volume":"106","author":"Chen","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2013.03.004_bib0470","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1089\/end.2009.0575","article-title":"Urethral strictures and bipolar transurethral resection in saline of the prostate: fact or fiction?","volume":"24","author":"Michielsen","year":"2010","journal-title":"J Endourol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0475","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1089\/end.2010.0714","article-title":"Complications and clinical outcome 18 months after bipolar and monopolar transurethral resection of the prostate","volume":"25","author":"Fagerstrom","year":"2011","journal-title":"J Endourol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0480","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.urology.2011.03.072","article-title":"Bipolar plasma vaporization vs monopolar and bipolar TURP\u2014a prospective, randomized, long-term comparison","volume":"78","author":"Geavlete","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2013.03.004_bib0485","doi-asserted-by":"crossref","first-page":"734","DOI":"10.3349\/ymj.2012.53.4.734","article-title":"Five-year follow-up results of a randomized controlled trial comparing bipolar plasmakinetic and monopolar transurethral resection of the prostate","volume":"53","author":"Xie","year":"2012","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.eururo.2013.03.004_bib0490","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.eururo.2007.08.036","article-title":"Holmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100 grams: 5-year follow-up results of a randomised clinical trial","volume":"53","author":"Kuntz","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0495","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.urology.2004.03.033","article-title":"Long-term results of open transvesical prostatectomy from a contemporary series of patients","volume":"64","author":"Varkarakis","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2013.03.004_bib0500","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.eururo.2006.04.003","article-title":"Holmium laser enucleation of the prostate versus open prostatectomy for prostates >70g: 24-month follow-up","volume":"50","author":"Naspro","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0505","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.urology.2006.08.1115","article-title":"Five-year follow-up of feedback microwave thermotherapy versus TURP for clinical BPH: a prospective randomized multicenter study","volume":"69","author":"Mattiasson","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2013.03.004_bib0510","first-page":"CD004135","article-title":"Microwave thermotherapy for benign prostatic hyperplasia","author":"Hoffman","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eururo.2013.03.004_bib0515","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/S0090-4295(98)00502-0","article-title":"Results of high energy transurethral microwave thermotherapy in patients categorized according to the American Society of Anaesthiologists operative risk classification","volume":"53","author":"D\u2019Ancona","year":"1999","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2013.03.004_bib0520","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/sj.pcan.4500293","article-title":"High energy transurethral thermotherapy in the treatment of benign prostatic hyperplasia: criteria to predict treatment outcome","volume":"2","author":"D\u2019Ancona","year":"1999","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2013.03.004_bib0525","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1464-410X.2004.04906.x","article-title":"A meta-analysis of trials of transurethral needle ablation for treating symptomatic benign prostatic obstruction","volume":"94","author":"Boyle","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2013.03.004_bib0530","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1471-2490-6-14","article-title":"Systematic review and meta-analysis of transurethral needle ablation in symptomatic benign prostatic hyperplasia","volume":"6","author":"Bouza","year":"2006","journal-title":"BMC Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0535","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000019832","article-title":"Transurethral needle ablation (TUNA). A critical review of radiofrequency thermal therapy in the management of benign prostatic hyperplasia","volume":"35","author":"Chapple","year":"1999","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0540","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/00005392-199707000-00029","article-title":"The early postoperative morbidity of transurethral resection of the prostate and of four minimally invasive treatment alternatives","volume":"158","author":"Schatzl","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0545","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1097\/01.ju.0000113494.03668.6d","article-title":"A systematic review of holmium laser prostatectomy for benign prostatic hyperplasia","volume":"171","author":"Tooher","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0550","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/01.ju.0000132739.57555.d8","article-title":"Holmium laser resection of the prostate versus transurethral resection of the prostate: results of a randomized trial with 4-year minimum long-term followup","volume":"172","author":"Westenberg","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0555","doi-asserted-by":"crossref","first-page":"a449","DOI":"10.1136\/bmj.39575.517674.BE","article-title":"Alternative approaches to endoscopic ablation for benign enlargement of the prostate: systematic review of randomised controlled trials","volume":"337","author":"Lourenco","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2013.03.004_bib0560","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/bjs.5916","article-title":"Meta-analysis of holmium laser enucleation versus transurethral resection of the prostate for symptomatic prostatic obstruction","volume":"94","author":"Tan","year":"2007","journal-title":"Br J Surg"},{"key":"10.1016\/j.eururo.2013.03.004_bib0565","doi-asserted-by":"crossref","unstructured":"Yin L, Teng J-F, Huang C-J, Zhang X, Xu D. Holmium laser enucleation of the prostate versus transurethral resection of the prostate: a systematic review and meta-analysis of randomized controlled trials. J Endourol. In press.","DOI":"10.1089\/end.2012.0505"},{"key":"10.1016\/j.eururo.2013.03.004_bib0570","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.juro.2012.02.2576","article-title":"Holmium laser enucleation versus photoselective vaporization for prostatic adenoma greater than 60ml: preliminary results of a prospective, randomized clinical trial","volume":"188","author":"Elmansy","year":"2012","journal-title":"J. Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0575","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1464-410X.2011.10359.x","article-title":"Long-term results of a randomized trial comparing holmium laser enucleation of the prostate and transurethral resection of the prostate: results at 7 years","volume":"109","author":"Gilling","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2013.03.004_bib0580","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1016\/j.juro.2011.06.065","article-title":"Holmium laser enucleation of the prostate: long-term durability of clinical outcomes and complication rates during 10 years of followup","volume":"186","author":"Elmansy","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0585","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.eururo.2006.03.028","article-title":"Current role of lasers in the treatment of benign prostatic hyperplasia (BPH)","volume":"49","author":"Kuntz","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0590","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/S0022-5347(05)00645-2","article-title":"Holmium laser enucleation of the prostate in patients on anticoagulant therapy or with bleeding disorders","volume":"175","author":"Elzayat","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0595","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1089\/end.2009.0013","article-title":"Safety of holmium laser enucleation of the prostate in anticoagulated patients","volume":"23","author":"Tyson","year":"2009","journal-title":"J Endourol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0600","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.eururo.2007.04.074","article-title":"Holmium laser enucleation of the prostate (HoLEP): long-term results, reoperation rate, and possible impact of the learning curve","volume":"52","author":"Elzayat","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0605","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1089\/end.2007.0262","article-title":"Holmium laser enucleation of the prostate: the safety, efficacy, and learning experience in China","volume":"22","author":"Du","year":"2008","journal-title":"J Endourol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0610","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.eururo.2012.04.051","article-title":"Photoselective vaporisation of the prostate using 80-W and 120-W laser versus transurethral resection of the prostate for benign prostatic hyperplasia: a systematic review with meta-analysis from 2002 to 2012","volume":"62","author":"Thangasamy","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0615","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/j.1464-410X.2009.08961.x","article-title":"A randomized trial of photoselective vaporization of the prostate using the 80-W potassium-titanylphosphate laser vs transurethral prostatectomy, with 1-year follow up","volume":"105","author":"Bouchier-Hayes","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2013.03.004_bib0620","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.eururo.2011.05.043","article-title":"GreenLight HPS 120-W laser vaporization versus transurethral resection of the prostate for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia: a randomized clinical trial with 2-year follow-up","volume":"60","author":"Capit\u00e1n","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0625","doi-asserted-by":"crossref","unstructured":"Skolarikos A, Alivizatos G, Chalikopoulos D et al., 80W PVP versus TURP: results of a randomized prospective study at 12 months of follow-up. Abstract presented at: American Urological Association annual meeting; May 17\u201322, 2008; Orlando, FL, USA.","DOI":"10.1016\/S0022-5347(08)61837-6"},{"key":"10.1016\/j.eururo.2013.03.004_bib0630","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.urology.2008.08.502","article-title":"Photoselective vaporization of prostate: five-year outcomes entire clinic patient population","volume":"73","author":"Hai","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2013.03.004_bib0635","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.eururo.2008.04.053","article-title":"GreenLight laser vaporisation of the prostate: single-center experience and long-term results after 500 procedures","volume":"54","author":"Ruszat","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0640","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.eururo.2010.05.026","article-title":"GreenLight HPS 120-W laser vaporization versus transurethral resection of the prostate for treatment of benign prostatic hyperplasia: a randomized clinical trial with midterm follow-up","volume":"58","author":"Al-Ansari","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0645","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1111\/j.1464-410X.2011.10878.x","article-title":"GreenLight HPS\u2122 120-W laser vaporization vs transurethral resection of the prostate (<60mL): a 2-year randomized double-blind prospective urodynamic investigation","volume":"110","author":"Pereira-Correia","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2013.03.004_bib0650","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.eururo.2011.11.041","article-title":"180-W XPS GreenLight laser therapy for benign prostate hyperplasia: early safety, efficacy, and perioperative outcome after 201 procedures","volume":"61","author":"Bachmann","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0655","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1089\/end.2010.0550","article-title":"Transurethral GreenLight laser enucleation of the prostate\u2014a feasibility study","volume":"25","author":"Brunken","year":"2011","journal-title":"J Endourol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0660","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.eururo.2006.01.019","article-title":"Photoselective vaporization of the prostate: subgroup analysis of men with refractory urinary retention","volume":"50","author":"Ruszat","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0665","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/01.ju.0000146631.14200.d4","article-title":"High power (80W) potassium-titanyl-phosphate laser vaporization of the prostate in 66 high risk patients","volume":"173","author":"Reich","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0670","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.eururo.2006.08.006","article-title":"Safety and effectiveness of photoselective vaporization of the prostate (PVP) in patients on ongoing oral anticoagulation","volume":"51","author":"Ruszat","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0675","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1464-410X.2007.06985.x","article-title":"Photoselective vaporization of the prostate with the potassium-titanyl-phosphate laser in men with prostates of >100mL","volume":"100","author":"Rajbabu","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2013.03.004_bib0680","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.juro.2011.04.068","article-title":"Outcomes and complications after 532nm laser prostatectomy in anticoagulated patients with benign prostatic hyperplasia","volume":"186","author":"Chung","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0685","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.eursup.2008.01.016","article-title":"Outcome of GreenLight HPS 120-W laser therapy in specific patient populations: those in retention, on anticoagulants, and with large prostates (>80ml)","volume":"7","author":"Woo","year":"2008","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.eururo.2013.03.004_bib0690","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.eururo.2011.10.009","article-title":"Laser treatment of benign prostatic obstruction: basics and physical differences","volume":"61","author":"Bach","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0695","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1464-410X.2009.08452.x","article-title":"Prospective single-centre comparison of 120-W diode-pumped solid-state high-intensity system laser vaporization of the prostate and 200-W high-intensive diode-laser ablation of the prostate for treating benign prostatic hyperplasia","volume":"104","author":"Ruszat","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2013.03.004_bib0700","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.urology.2009.09.033","article-title":"Preliminary results of prostate vaporization in the treatment of benign prostatic hyperplasia by using a 200-W high-intensity diode laser","volume":"75","author":"Chen","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2013.03.004_bib0705","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/lsm.22081","article-title":"High-intensity diode laser in combination with bipolar transurethral resection of the prostate: a new strategy for the treatment of large prostates (>80ml)","volume":"44","author":"Chen","year":"2012","journal-title":"Lasers Surg Med"},{"key":"10.1016\/j.eururo.2013.03.004_bib0710","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/lsm.20940","article-title":"GreenLight HPS laser 120-W versus diode laser 200-W vaporization of the prostate: comparative clinical experience","volume":"42","author":"Chiang","year":"2010","journal-title":"Lasers Surg Med"},{"key":"10.1016\/j.eururo.2013.03.004_bib0715","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.juro.2009.05.043","article-title":"High power diode laser vaporization of the prostate: preliminary results for benign prostatic hyperplasia","volume":"182","author":"Erol","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0720","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/pcan.2009.5","article-title":"Preliminary results on selective light vaporization with the side-firing 980nm diode laser in benign prostatic hyperplasia: an ejaculation sparing technique","volume":"12","author":"Leonardi","year":"2009","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2013.03.004_bib0725","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.eururo.2007.06.028","article-title":"The diode laser: a novel side-firing approach for laser vaporisation of the human prostate\u2014immediate efficacy and 1-year follow-up","volume":"52","author":"Seitz","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0730","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.juro.2011.09.153","article-title":"Quartz head contact laser fiber: a novel fiber for laser ablation of the prostate using the 980nm high power diode laser","volume":"187","author":"Shaker","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0735","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.eururo.2012.08.049","article-title":"Eraser laser enucleation of the prostate: technique and results","volume":"63","author":"Hruby","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0740","doi-asserted-by":"crossref","first-page":"752","DOI":"10.4111\/kju.2011.52.11.752","article-title":"Initial experiences with a 980nm diode laser for photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia","volume":"52","author":"Yang","year":"2011","journal-title":"Korean J Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0745","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1016\/j.juro.2011.07.026","article-title":"Safety and efficacy of eraser laser enucleation of the prostate: preliminary report","volume":"186","author":"Lusuardi","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0750","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.eururo.2007.05.019","article-title":"Thulium laser versus standard transurethral resection of the prostate: a randomized prospective trial","volume":"53","author":"Xia","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0755","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.urology.2009.07.1266","article-title":"Comparison of 2-microm continuous wave laser vaporesection of the prostate and transurethral resection of the prostate: a prospective nonrandomized trial with 1-year follow-up","volume":"75","author":"Fu","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2013.03.004_bib0760","doi-asserted-by":"crossref","unstructured":"Peng B, Wang G-C, Zheng J-H, et al. A comparative study of thulium laser resection of the prostate and bipolar transurethral plasma kinetic prostatectomy for treating benign prostatic hyperplasia. BJU Int. In press. http:\/\/dx.doi.org\/10.1111\/j.1464-410X.2012.11610.x.","DOI":"10.1111\/j.1464-410X.2012.11610.x"},{"key":"10.1016\/j.eururo.2013.03.004_bib0765","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1016\/j.juro.2011.07.073","article-title":"Thulium: YAG vapoenucleation in large volume prostates","volume":"186","author":"Bach","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0770","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1159\/000336874","article-title":"Thulium laser (Revolix) vapoenucleation of the prostate is a safe procedure in patients with an increased risk of hemorrhage","volume":"88","author":"Hauser","year":"2012","journal-title":"Urol Int"},{"key":"10.1016\/j.eururo.2013.03.004_bib0775","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1089\/end.2011.0173","article-title":"Comparison of 120\u2013200W 2\u03bcm thulium:yttrium-aluminum-garnet vapoenucleation of the prostate","volume":"26","author":"Netsch","year":"2012","journal-title":"J Endourol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0780","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1464-410X.2011.10767.x","article-title":"120-W 2-\u03bcm thulium:yttrium-aluminium-garnet vapoenucleation of the prostate: 12-month follow-up","volume":"110","author":"Netsch","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2013.03.004_bib0785","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.urology.2011.12.018","article-title":"Thulium laser versus holmium laser transurethral enucleation of the prostate: 18-month follow-up data of a single center","volume":"79","author":"Zhang","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2013.03.004_bib0790","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.eururo.2008.10.034","article-title":"Endoscopic vaporesection of the prostate using the continuous-wave 2-mm thulium laser: outcome and demonstration of the surgical technique","volume":"55","author":"Szlauer","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0795","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00345-009-0461-6","article-title":"Thulium: YAG laser enucleation (VapoEnucleation) of the prostate: safety and durability during intermediate-term follow-up","volume":"28","author":"Bach","year":"2010","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0800","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.juro.2007.01.005","article-title":"Epithelializing stent for benign prostatic hyperplasia: a systematic review of the literature","volume":"177","author":"Armitage","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0805","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/j.1464-410X.2006.06399.x","article-title":"The thermo-expandable metallic stent for managing benign prostatic hyperplasia: a systematic review","volume":"98","author":"Armitage","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2013.03.004_bib0810","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MOU.0b013e3280117747","article-title":"Prostatic stents for the treatment of benign prostatic hyperplasia","volume":"17","author":"vanderBrink","year":"2007","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0815","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.eururo.2004.06.001","article-title":"Evaluation of the transurethral ethanol ablation of the prostate (TEAP) for symptomatic benign prostatic hyperplasia (BPH): a European multi-center evaluation","volume":"46","author":"Grise","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0820","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s11255-008-9394-z","article-title":"Transurethral ethanol ablation of the prostate (TEAP): an effective minimally invasive treatment alternative to traditional surgery for symptomatic benign prostatic hyperplasia (BPH) in high-risk comorbidity patients","volume":"40","author":"Magno","year":"2008","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0825","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1089\/end.2010.0201","article-title":"Transurethral ethanol ablation of the prostate for symptomatic benign prostatic hyperplasia: long-term follow-up","volume":"25","author":"El-Husseiny","year":"2011","journal-title":"J Endourol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0830","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1097\/01.ju.0000134884.18722.9c","article-title":"Transurethral ethanol injection therapy for prostatic hyperplasia: 3-year results","volume":"172","author":"Goya","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0835","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/S0022-5347(05)00318-6","article-title":"Novel action of botulinum toxin on the stromal and epithelial components of the prostate gland","volume":"175","author":"Chuang","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0840","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/nau.21142","article-title":"The use of botulinum toxin in benign prostatic hyperplasia","volume":"31","author":"Marchal","year":"2012","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2013.03.004_bib0845","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.juro.2011.04.062","article-title":"Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia: a phase II randomized clinical trial","volume":"186","author":"Crawford","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0850","doi-asserted-by":"crossref","first-page":"463574","DOI":"10.1100\/2012\/463574","article-title":"Botulinum neurotoxin type a for the treatment of benign prostatic hyperplasia: randomized study comparing two doses","volume":"2012","author":"Arnouk","year":"2012","journal-title":"ScientificWorldJournal"},{"key":"10.1016\/j.eururo.2013.03.004_bib0855","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.eururo.2012.10.005","article-title":"A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia","volume":"63","author":"Marberger","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0860","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.eururo.2008.06.016","article-title":"Is botulinum neurotoxin type A (BoNT-A) a novel therapy for lower urinary tract symptoms due to benign prostatic enlargement? A review of the literature","volume":"54","author":"Oeconomou","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.03.004_bib0865","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1111\/j.1464-410X.2010.09841.x","article-title":"Intraprostatic botulinum toxin type A administration: evaluation of the effects on sexual function","volume":"107","author":"Silva","year":"2011","journal-title":"BJU Int"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283813002285?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283813002285?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T19:06:35Z","timestamp":1562785595000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283813002285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":173,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S0302283813002285"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2013.03.004","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}